logo
logo
Pediatrix Medical Group, Inc.

Pediatrix Medical Group, Inc.

NYSE•MD
CEO: Mr. Mark S. Ordan
セクター: Healthcare
業種: Medical - Care Facilities
上場日: 1995-09-20
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals, including pediatric nurse practitioners, echocardiographers, other diagnostic technicians, and exercise physiologists; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians, pediatric gastroenterologists; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
連絡先情報
1301 Concord Terrace, Sunrise, FL, 33323, United States
954-384-0175
www.pediatrix.com
時価総額
$1.86B
PER (TTM)
11.4
17
配当利回り
--
52週高値
$24.99
52週安値
$11.84
52週レンジ
75%
順位46Top 59.5%
3.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$492.88M-3.58%
直近4四半期の推移

EPS

$0.85+269.56%
直近4四半期の推移

フリーCF

$131.95M+54.24%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Net Income Reverses Loss Nine months net income $131.7M versus prior year net loss of $(129.5M); significant profitability turnaround achieved across operations.
Adjusted EBITDA Strong Growth Nine months Adjusted EBITDA reached $209.7M, showing substantial growth from $155.3M last year period due to favorable unit results.
Cash Position Strengthened Cash and equivalents $340.1M as of September 30, 2025, representing a net increase of $110.2M from year-end 2024.

リスク要因

Revenue Impact From Dispositions Nine months revenue fell $90.5M (6.0%) due to non-same unit activity from practice dispositions completed during 2024.
Regulatory Billing Uncertainty Surprise Billing Legislation (NSA) and potential Medicaid reform changes create uncertainty regarding future payment rates and collections.
Legal Malpractice Exposure Pending legal actions, especially malpractice claims, could result in unfavorable resolutions materially affecting financial condition.

見通し

Liquidity Supports Operations $450.0M available on Revolving Credit Line; liquidity sufficient to finance working capital and contractual obligations for 12 months.
Strategic Focus Shift Organization renewed focus on hospital-based and maternal-fetal businesses following completion of office practice exits in 2024.
Share Repurchase Authorization $229.1M remains authorized for share repurchases under recent August 2025 board authorization; timing depends on market conditions.

同業比較

売上高 (TTM)

Ardent Health Partners, Inc.ARDT
$6.33B
+10.9%
Organon & Co.OGN
$6.22B
-2.9%
Select Medical Holdings CorporationSEM
$3.93B
-35.0%

粗利益率 (最新四半期)

Acadia Healthcare Company, Inc.ACHC
96.4%
+0.1pp
GoodRx Holdings, Inc.GDRX
93.2%
-0.9pp
Novavax, Inc.NVAX
69.5%
+41.2pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
LFST$2.74B-298.8-0.6%22.0%
NHC$2.56B25.210.0%8.1%
ADUS$2.09B24.38.5%14.2%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-0.6%
横ばい
4四半期純利益CAGR
33.0%
収益性の大幅な改善
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年2月19日
|
EPS:$0.53
|
売上高:$486.23M
財務レポート
財務データ
ニュース
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月3日|
    売上高: $492.88M-3.6%
    |
    EPS: $0.85+269.6%
    予想を上回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月5日|
    売上高: $468.84M-7.0%
    |
    EPS: $0.45-124.5%
    予想を上回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月6日|
    売上高: $458.36M-7.4%
    |
    EPS: $0.24+380.0%
    予想通り
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月20日|
    売上高: $2.01B+0.9%
    |
    EPS: $-1.19-65.3%
    予想を下回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月1日|
    売上高: $511.16M+0.9%
    |
    EPS: $0.23-11.5%
    予想を下回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|
    売上高: $504.30M+0.7%
    |
    EPS: $-1.84-641.2%
    予想を下回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $495.10M+0.8%
    |
    EPS: $0.05-70.6%
    予想を下回る
  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月20日|
    売上高: $1.99B+1.1%
    |
    EPS: $-0.72-190.0%
    予想を下回る